Citadel Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-77,599
| Closed | -$144K | – | 15718 |
|
|
2023
Q1 | $144K | Buy |
77,599
+68,655
| +768% | +$85K | ﹤0.01% | 10712 |
|
|
2022
Q4 | $9.93K | Sell |
8,944
-1,446,918
| -99% | -$2.06M | ﹤0.01% | 13653 |
|
|
2022
Q3 | $3.41M | Sell |
1,455,862
-239,005
| -14% | -$846K | ﹤0.01% | 4552 |
|
|
2022
Q2 | $5.14M | Sell |
1,694,867
-6,687
| -0.4% | -$32.5K | ﹤0.01% | 3743 |
|
|
2022
Q1 | $11.6M | Sell |
1,701,554
-27,482
| -2% | -$196K | ﹤0.01% | 2736 |
|
|
2021
Q4 | $14.4M | Buy |
1,729,036
+4,785
| +0.3% | +$39.4K | ﹤0.01% | 2475 |
|
|
2021
Q3 | $12.8M | Sell |
1,724,251
-236,350
| -12% | -$1.46M | ﹤0.01% | 2649 |
|
|
2021
Q2 | $13.3M | Buy |
1,960,601
+54
| +0% | +$449 | ﹤0.01% | 2642 |
|
|
2021
Q1 | $20.1M | Buy |
1,960,547
+229,198
| +13% | +$2.51M | ﹤0.01% | 1955 |
|
|
2020
Q4 | $12.1M | Buy |
1,731,349
+1,694,224
| +4,564% | +$13.2M | ﹤0.01% | 2392 |
|
|
2020
Q3 | $303K | Sell |
37,125
-416,777
| -92% | -$2.58M | ﹤0.01% | 8117 |
|
|
2020
Q2 | $3.13M | Buy |
453,902
+412,056
| +985% | +$2.22M | ﹤0.01% | 3781 |
|
|
2020
Q1 | $198K | Buy |
41,846
+30,230
| +260% | +$174K | ﹤0.01% | 8023 |
|
|
2019
Q4 | $101K | Buy |
11,616
+947
| +9% | +$5.12K | ﹤0.01% | 8545 |
|
|
2019
Q3 | $36K | Sell |
10,669
-15,335
| -59% | -$61.4K | ﹤0.01% | 8797 |
|
|
2019
Q2 | $129K | Sell |
26,004
-52,709
| -67% | -$280K | ﹤0.01% | 8429 |
|
|
2019
Q1 | $488K | Sell |
78,713
-7,845
| -9% | -$37.9K | ﹤0.01% | 6825 |
|
|
2018
Q4 | $292K | Sell |
86,558
-132,872
| -61% | -$621K | ﹤0.01% | 7322 |
|
|
2018
Q3 | $1.43M | Sell |
219,430
-314,941
| -59% | -$2.34M | ﹤0.01% | 4942 |
|
|
2018
Q2 | $4.09M | Buy |
534,371
+241,786
| +83% | +$3.49M | ﹤0.01% | 3036 |
|
|
2018
Q1 | $6.54M | Buy |
+292,585
| New | +$6.49M | ﹤0.01% | 2163 |
|
|
2017
Q3 | – | Sell |
-14,245
| Closed | -$200K | – | 8209 |
|
|
2017
Q2 | $200K | Buy |
+14,245
| New | +$305K | ﹤0.01% | 6572 |
|
Other funds holding JNCE
Citadel Advisors's JNCE Position: Q2 2023 in Review
Citadel Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 77,599 shares — an estimated $144K sold.
Citadel Advisors first reported a position in JNCE in Q2 2017 and held it in 22 quarters. The position peaked at $20.1M in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Citadel Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 77,599 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $144K.
- Citadel Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 22 quarters.
- Citadel Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $20.1M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.